Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

Methadone not forgotten as health officials push for buprenorphine expansion
09/19/2014
While targeting the effort to lift limits on buprenorphine prescribing, public health officials from major metropolitan areas this week affirmed methadone's critical role in the continuum of service.
While targeting the effort to lift limits on buprenorphine prescribing, public health officials from major metropolitan areas this week affirmed methadone's critical role in the continuum of service.
While targeting the effort to...
09/19/2014
Addiction Professional
News
Study will probe long-term brain changes in addiction
09/08/2014
It is hoped that a federal grant for research into brain rewiring that contributes to relapse could help identify therapies for cocaine addiction.
It is hoped that a federal grant for research into brain rewiring that contributes to relapse could help identify therapies for cocaine addiction.
It is hoped that a federal grant...
09/08/2014
Addiction Professional
News
Drug company moves forward in testing implant treatment for opioid addiction
07/22/2014
A new Phase 3 trial is under way for Probuphine, a subdermal implant treatment for opioid addiction that did not pass federal review in 2013.
A new Phase 3 trial is under way for Probuphine, a subdermal implant treatment for opioid addiction that did not pass federal review in 2013.
A new Phase 3 trial is under way...
07/22/2014
Addiction Professional
News
Millennium expands on test to predict medication response
07/18/2014
Drug testing company Millennium Laboratories now incorporates 11 genes into its pharmacogenetic test for evaluating potential response to medication treatments, including those for addiction.
Drug testing company Millennium Laboratories now incorporates 11 genes into its pharmacogenetic test for evaluating potential response to medication treatments, including those for addiction.
Drug testing company Millennium...
07/18/2014
Addiction Professional
Be wary of lifting cap on buprenorphine patients, AATOD paper warns
07/09/2014
A new policy paper from the American Association for the Treatment of Opioid Dependence (AATOD) addresses several timely policy debates on opioid addiction and its treatment, including the merits of federal restrictions on the prescribing of...
A new policy paper from the American Association for the Treatment of Opioid Dependence (AATOD) addresses several timely policy debates on opioid addiction and its treatment, including the merits of federal restrictions on the prescribing of...
A new policy paper from the...
07/09/2014
Addiction Professional
News
Study identifies smokers most likely to benefit from combination treatments
06/17/2014
Research released today indicates that men and the highly nicotine-dependent may benefit most from combination therapies for smoking cessation after an unsuccessful trial of a single intervention.
Research released today indicates that men and the highly nicotine-dependent may benefit most from combination therapies for smoking cessation after an unsuccessful trial of a single intervention.
Research released today...
06/17/2014
Addiction Professional
Active buprenorphine market continues with approval of new mode of administration
06/11/2014
An experienced prescriber of buprenorphine for opioid dependence believes a new formulation that will dissolve in a patient's cheek could represent a breakthrough in treatment.
An experienced prescriber of buprenorphine for opioid dependence believes a new formulation that will dissolve in a patient's cheek could represent a breakthrough in treatment.
An experienced prescriber of...
06/11/2014
Addiction Professional
News
Reckitt Benckiser enters agreement to develop naloxone nasal spray
05/21/2014
The pharmaceutical company plans to co-develop a nasal spray alternative to the overdose reversal medication that has become an important component of the public health response to the opioid crisis.
The pharmaceutical company plans to co-develop a nasal spray alternative to the overdose reversal medication that has become an important component of the public health response to the opioid crisis.
The pharmaceutical company plans...
05/21/2014
Addiction Professional
News
Reckitt Benckiser enters license agreement for alcohol use drug
05/16/2014
The pharmaceutical company plans to initiate a Phase IIB proof-of-concept study of the medication arbaclofen placarbil.
The pharmaceutical company plans to initiate a Phase IIB proof-of-concept study of the medication arbaclofen placarbil.
The pharmaceutical company plans...
05/16/2014
Addiction Professional
Federal agencies see medication treatments as key antidote to opioid crisis
04/30/2014
A commentary from four agencies under the U.S. Department of Health and Human Services (HHS) suggests that the physician community must play a major role in reversing the epidemic of opioid addiction and overdose.
A commentary from four agencies under the U.S. Department of Health and Human Services (HHS) suggests that the physician community must play a major role in reversing the epidemic of opioid addiction and overdose.
A commentary from four agencies...
04/30/2014
Addiction Professional

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement